PolymarketBeschikbaarheid controlerenGeen KYCGeverifieerde afwikkelingsgegevensGoed gekalibreerdWaarschuwing datakwaliteitGeen actuele koersen
Gegevens van 5 okt 2026, 21:30 UTC · beleid pm-quality-4
Huidige impliciete kans
June 30, 83%
June 30, 83%Marktkwaliteit
≤49 / 100
Lage kwaliteit24u volume
—
Liquiditeit
€ 6,8K
Gemiddelde liquiditeitBied / Laat
82.0% / 83.0%
Spread
1.0 pt
Strakke spreadReacties
0
Marktdata
Bijgewerkt 13 minuten geleden
19 aug 26, 18:47 UTC1 jul 27, 03:59 UTC
Trends
Voorwaarden van het handelsplatform
Bron: Polymarket
Deze voorwaarden zijn ter informatie; voor gesimuleerd handelen bij CoinRithm gelden eigen regels.
- Minimumorder (aandelen):
- 5
- Prijsstap:
- 1 procentpunten
- Kosten:
- Ja
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
FDA approves skin cancer vaccine by which date?
PolymarketIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWill the Russian cancer vaccine work?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsWhat will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold MarketsWill CDC cut the childhood vaccine schedule below 11 diseases in 2026?
KalshiRegels
This market will resolve to "Yes" if it is officially announced that a Biologics License Application (BLA) for intismeran autogene has been submitted to the U.S. Food and Drug Administration (FDA), or that the FDA has accepted such an application for review, by June 30, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- A qualifying application must seek FDA licensure of intismeran autogene through a Biologics License Application (BLA).
- An original BLA or a resubmission of such a BLA following FDA action will qualify.
- The application may cover any indication.